Mandatory NPO for at least 8 hours. Comprehensive pre-operative imaging including pelvic MRI, CT, and PET-CT for oncological staging. Blood typing and cross-matching for potential massive transfusion. Prophylactic intravenous antibiotics within 60 minutes of incision. Deep vein thrombosis prophylaxis initiated 12 hours pre-operatively.
Post-operative monitoring in ICU for 24-48 hours. Strict non-weight bearing on the affected limb for at least 6-8 weeks. Multimodal pain management including nerve blocks or epidural analgesia. Intensive physical therapy starting on post-operative day 2. Early mobilization with assistive devices. Monitor for surgical site infection and neurovascular integrity of the lower extremity.
Comprehensive Clinical Guide: Type II Pelvic Resection (Periacetabular)
1. Introduction and Overview
Type II Pelvic Resection, commonly referred to as a periacetabular resection, represents one of the most complex and demanding procedures in orthopedic oncology and reconstructive surgery. The procedure involves the en bloc removal of the acetabulum—the cup-shaped socket of the hip bone—along with surrounding periacetabular bone, typically due to primary bone sarcomas (such as chondrosarcoma, osteosarcoma, or Ewing sarcoma) or aggressive locally destructive benign tumors (such as giant cell tumors or recurrent metastatic disease).
Because the acetabulum serves as the critical load-bearing bridge between the axial skeleton (the spine) and the appendicular skeleton (the lower limb), its resection creates a massive structural void. The primary goal of this surgery is achieving a negative oncological margin (R0 resection) while attempting to maintain or restore the functional integrity of the hip joint and the patient’s ability to ambulate.
2. Technical Specifications and Anatomical Considerations
The Enneking classification system for pelvic resections defines a Type II resection as an isolated resection of the periacetabular region. Unlike Type I (ilium) or Type III (pubis/ischium) resections, the Type II procedure disrupts the weight-bearing axis of the hip.
Key Anatomical Landmarks
- The Triradiate Cartilage (in pediatric patients): Often serves as the boundary for resection.
- The Sciatic Nerve: Runs directly posterior to the acetabulum; extreme vigilance is required during the posterior dissection.
- The Femoral Vessels: Located anteriorly, requiring meticulous retraction and potential vascular bypass if tumor involvement is extensive.
- The Pelvic Ring: Integrity must be assessed to determine if internal stabilization or custom endoprosthetic replacement is feasible.
Surgical Modalities for Reconstruction
Once the tumor is excised, the surgeon must choose between several reconstructive strategies:
1. Saddle Prosthesis: A classic technique where a custom-made metal implant "sits" on the remaining ilium, bypassing the acetabulum.
2. Custom 3D-Printed Titanium Implants: The current gold standard, allowing for patient-specific anatomical matching and improved osseointegration.
3. Allograft-Prosthetic Composite (APC): Utilizing a massive bone allograft combined with a total hip arthroplasty (THA).
4. Pseudoarthrosis (Girdlestone Procedure): Reserved for patients where reconstruction is impossible; it involves removing the hip joint and allowing the femur to scar into the pelvic soft tissues, sacrificing stability for pain relief.
3. Clinical Indications and Patient Selection
Primary Indications
- Primary Malignant Bone Tumors: Chondrosarcoma (low-to-intermediate grade), Osteosarcoma, and Ewing Sarcoma.
- Aggressive Benign Tumors: Giant Cell Tumor of Bone (GCTB) that has destroyed the acetabular subchondral bone.
- Pathological Fractures: Resulting from metastatic disease where the pelvic ring is compromised.
Patient Selection Criteria
Candidates must undergo rigorous multi-disciplinary evaluation:
| Factor | Requirement |
| :--- | :--- |
| Performance Status | ECOG score of 0-2 preferred for major resection. |
| Vascular/Nerve Status | Pre-operative MRI/CT angiography to ensure no encasement of external iliac vessels. |
| Nutritional Status | Albumin/Pre-albumin levels must be optimized to ensure wound healing. |
| Oncological Status | Absence of distant metastatic disease (unless palliative). |
4. Pre-Operative Preparation
Preparation for a Type II resection is a multi-week process involving:
1. Imaging: High-resolution CT with 3D reconstruction and MRI with contrast to delineate soft tissue involvement.
2. Biopsy: Core needle biopsy is mandatory, preferably performed by the surgeon who will perform the resection to minimize contamination of the surgical approach.
3. Embolization: If the tumor is highly vascular (e.g., renal cell metastasis or aggressive GCTB), pre-operative selective arterial embolization is performed to reduce intraoperative blood loss.
4. Autologous Blood Banking: Due to the risk of massive hemorrhage, patients are encouraged to donate blood pre-operatively.
5. The Procedure: Surgical Steps
Step 1: Approach
The choice of approach depends on the tumor location.
* Ilioinguinal Approach: Best for anterior involvement and vascular exposure.
* Posterior (Kocher-Langenbeck) Approach: Best for posterior acetabular involvement and sciatic nerve protection.
* Combined Approach: Often necessary for extensive Type II lesions.
Step 2: Osteotomies
Using high-speed burrs and oscillating saws, the surgeon performs the osteotomies:
* Superior: Through the ilium, above the acetabulum.
* Inferior: Through the superior and inferior pubic rami (ischiopubic ramus).
* Medial: Through the pelvic brim to the sciatic notch.
Step 3: Resection and Margin Assessment
The specimen is removed en bloc. Frozen sections are taken from the margins to ensure the tumor has been cleared.
Step 4: Reconstruction
The chosen reconstructive device (e.g., 3D-printed titanium cage) is fixed to the remaining ilium and the intact portion of the pelvic ring using locking plates and screws. If a total hip arthroplasty component is involved, the femoral stem is inserted into the femur and articulated with the new acetabular component.
6. Post-Operative Recovery Protocol
Recovery is extensive and often requires 6-12 months for stabilization.
- Phase I (Weeks 0-6): Strict non-weight bearing on the affected side. Focus on wound healing and deep vein thrombosis (DVT) prophylaxis.
- Phase II (Weeks 6-12): Gradual transition to partial weight-bearing with crutches or a walker, pending radiographic evidence of implant integration.
- Phase III (Months 3-12): Progressive physical therapy focusing on gluteal strengthening and gait normalization.
7. Risks and Potential Complications
Type II pelvic resection is associated with a high morbidity rate, primarily due to the anatomical complexity.
- Neurological Injury: Transient or permanent sciatic or femoral nerve palsy.
- Wound Complications: Necrosis or infection, particularly if the patient has received prior radiotherapy.
- Implant Failure: Mechanical loosening or breakage of the pelvic prosthesis.
- Hemorrhage: Massive blood loss requiring massive transfusion protocols.
- Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE): Elevated risk due to the duration of surgery and pelvic venous manipulation.
8. Alternative Treatments
- Radiotherapy: Often used for radiosensitive tumors (e.g., Ewing Sarcoma) or as an adjunct to surgery.
- Chemotherapy: The standard of care for osteosarcoma and Ewing sarcoma to shrink the primary tumor and treat micrometastases.
- Radiofrequency Ablation (RFA): Used for small, localized, benign, or palliative lesions.
- Cryotherapy: Sometimes used as an adjunct to intralesional curettage for benign aggressive tumors, though not suitable for large Type II malignancies.
9. Frequently Asked Questions (FAQ)
1. How long is the surgery?
Typically, the procedure lasts between 6 to 12 hours, depending on the complexity of the reconstruction and the extent of the tumor.
2. What is the success rate of this surgery?
Success is measured by local control of the tumor and functional outcome. Local control rates for malignant tumors are generally 70-85% with modern surgical techniques.
3. Will I be able to walk normally after a Type II resection?
Most patients require a cane or crutch for long distances. Gait will be altered, but the goal is to achieve a pain-free, stable hip joint.
4. What are the signs of an implant infection?
Persistent drainage, redness around the incision, fever, or sudden onset of hip pain after initial recovery.
5. How often will I need follow-up appointments?
Initially, every 3 months for the first two years, then every 6 months, focusing on both oncological surveillance and hardware integrity.
6. Is a 3D-printed implant better than a standard saddle prosthesis?
Yes, 3D-printed implants allow for superior fit and biological fixation, leading to better long-term stability than the older, non-fixed saddle designs.
7. Can this surgery be performed minimally invasively?
Generally, no. The need for wide margins and the necessity of protecting neurovascular bundles requires a formal, extensive open approach.
8. What is the biggest risk during the procedure?
Intraoperative hemorrhage is the most immediate threat, followed by the risk of sciatic nerve injury.
9. How is the sciatic nerve protected?
The nerve is identified early in the procedure and carefully retracted with soft rubber loops to prevent mechanical stretching or thermal injury.
10. What happens if the tumor returns?
Local recurrence is a significant challenge. Treatment options may include revision surgery, additional radiotherapy, or systemic therapy depending on the tumor type.
10. Conclusion
Type II Pelvic Resection (Periacetabular) remains a pinnacle of orthopedic oncology. While the surgical risks are substantial, the advent of 3D-printing technology and multidisciplinary care has transformed the prognosis for patients facing these aggressive lesions. Success relies not just on the technical execution of the osteotomies, but on a well-orchestrated pre-operative plan and a dedicated post-operative rehabilitation team. Patients should be treated at high-volume specialized sarcoma centers to optimize outcomes and minimize the significant potential for complications.